Collegium Pharmaceutical's wisdom is in developing over-the-counter and prescription drugs for a variety of conditions affecting the skin and central nervous and respiratory systems. Typically the company starts with existing drugs and works to improve them through new delivery systems that modify their release, or prevent abuse. It is working with drugs to treat such conditions as fibromyalgia, pain, and sleep apnea. Through its subsidiary Onset Therapeutics, the company markets wound care and dermatology (acne, skin infections) drugs. Its topical aerosol product Exactacain is licensed and sold by Healthpoint while its approved allergy nasal spray AllerNaze is licensed to Lupin Ltd.

Synteract, Inc. company has overseen hundreds of projects for clients that include biotechnology and pharmaceutical companies, as well as medical device makers. On top of research services, Synteract offers clients proprietary and customizable software solutions for managing research and trial data. The company's expertise covers a wide range of health issues, including oncology, HIV/AIDS, ophthalmology, and gastrointestinal disorders. Founded in 1995, Synteract maintains offices in San Diego, Philadelphia, and North Carolina.

Novogen Limited company was founded in 1994 and is headquartered in North Ryde, Australia. Novogen Limited is engaged in pharmaceutical research and development, and marketing of consumer healthcare products. In February, 2009, the Company announced that it focuses its activities on its oncology program. The Company operates subsidiary companies in 3 geographical areas: Australia, North America and Europe. The subsidiaries are involved in the selling and marketing of Novogen's consumer healthcare products. The Company’s product range includes Phenoxodiol, Triphendiol, NV-128, and GLYC-101. The Company’s subsidiaries include Novogen Laboratories Pty Ltd, Norvogen Pty Ltd, Glycotex, Inc. and Novogen BV.

ARIUS Research Inc. company was founded in 1999 and is based in Toronto, Canada. As of September 23, 2008, Arius Research Inc. operates as a subsidiary of Roche Holding AG. ARIUS Research, Inc., a biotechnology company, engages in the discovery and development of antibody therapeutics primarily focusing on breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma. It identifies monoclonal antibodies targeting various cancer indications through its technology platform, FunctionFIRST. The company’s product pipeline includes CD63 program that is in preclinical studies for various cancer indications; ARH460-16-2, an antibody targeting the cancer stem cell antigen CD44; AR36A36.11.1 and AR10A304.7, which targets the complement-inhibitory molecule CD59; AR47A6.4.2 and AR52A301.5, which are monoclonal antibodies directed to the cancer-associated protein TROP-2 that is homologous to human EpCAM, an another cell surface cancer related protein; and AR40A746.2.3 that targets leukemia cancer stem cells. It also has antibody programs targeting the MCSP antigen and 37LRP. ARIUS has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Inc., Medarex, Inc., Genentech, Inc., and Takeda Pharmaceutical Company Limited.

Columbia Laboratories, Inc. company was founded in 1986 and is based in Livingston, New Jersey. Columbia Laboratories, Inc. engages in the research, development, and commercialization of women's healthcare and endocrinology products. Its products are used to treat infertility, endometriosis, dysmenorrhea, preterm birth for women with a short cervix at mid-pregnancy, and hormonal deficiencies. The company's products primarily utilize its patented Bioadhesive Delivery System technology. The company markets vaginal progesterone gel products to assist women who are infertile become pregnant in the United States, which include CRINONE 8% for technical procedures to reproductive endocrinologists; PROCHIEVE 8% to obstetricians and gynecologists; and PROCHIEVE 4% for treatment of secondary amenorrhea. It also provides vaginal gel women's products, such as Replens, a vaginal moisturizer for replenishment of vaginal moisture; RepHresh vaginal gel that eliminates vaginal odor; and Advantage-S, a female contraceptive gel. In addition, the company offers STRIANT, a testosterone buccal system for the treatment of hypogonadism in men; and Advance Formula Legatrin PM for the relief of occasional pain and sleeplessness associated with minor muscle aches. Further, it engages in clinical development activities of vaginally-administered lidocaine to prevent and treat dysmenorrhea, as well as vaginally-administered carbamide peroxide for treating vaginal infections; and testosterone progressive hydration vaginal tablet for women, which completed phase I trial.

Lexicon Pharmaceuticals, Inc company was founded in 1995 and is headquartered in The Woodlands, Texas. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which is in a Phase II clinical trial for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX1032 that has completed Phase I clinical trials to treat the symptoms associated with carcinoid syndrome; LX2931, which is in Phase I clinical trial for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX4211 that is in Phase 1 clinical trials to treat Type 2 diabetes. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. Lexicon Pharmaceuticals has drug discovery alliances with Bristol-Myers Squibb Company to discover, develop, and commercialize small molecule drugs in the neuroscience field; and N.V. Organon to discover, develop, and commercialize new biotherapeutic drugs. It also has an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Amgen GmbH speaks the language of biotech geeks, only with a German accent. Amgen GmbH is a German unit of US-based Amgen, the world's largest biotech company. The subsidiary was established in 1989 to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen and Aranesp, for the treatment of anemia in people with chronic kidney disease; Neupogen and Neulasta, to help restore white blood cell counts for cancer patients; and Enbrel, for the treatment of psoriasis and rheumatoid arthritis.

Celgene Signal Research (also known as Celgene Research San Diego) wouldn't want it any other way. This Celgene division works to identify potential drug candidates with a focus on regulating genes and the production of disease-causing proteins. Much of its work has been to identify and map certain kinase and ligase proteins, which future Celgene drugs are then designed to inhibit. Celgene Signal Research's drug discovery programs target inflammatory diseases, as well as cancers such as leukemia.

AES Laboratoire produces and distributes a complete range of microbial testing instruments and equipment. Whether for quality assurance or national security, clients from 21 countries in industries from food production to pharmaceuticals contract with AES to assure the quality and safety of products and to monitor possible hazards in various working environments. AES is developing and patenting technologies that are more accurate and less time-consuming than traditional laboratory testing methods, including machines that sample the air for bio-contaminants and chemical "litmus tests" that can quickly detect and identify pathogens.

Cangene Corporation company makes plasma products known as hyperimmunes, which are antibody preparations and recombinant biopharmaceuticals made by introducing a gene in a host organism. Cangene's drugs are used to treat plasma-derived disorders, including the blood clotting disorder thrombocytopenic purpura and hemolytic disease of the newborn, which occurs when a fetus' blood type is incompatible with its mother's. Cangene has several approved products and is developing others, mainly in the areas of infectious disease and biodefense. Generic giant Apotex owns more than 80% of Cangene.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.